337.20 3.20 (0.96%)

25.10% Gain from 52W Low

3.3M NSE+BSE Volume

NSE 03 Jun, 2025 3:31 PM (IST)

Regulatory Approval
Biocon receives CDSCO nod for Liraglutide, used to treat Type 2 diabetes in adults and children See details


Biocon Ltd. Corporate Filings & Announcements

Latest corporate announcements and filings from Biocon Ltd. on BSE

announcement
Get corporate announcements alerts
Load latest
716 Votes:
Buy 75.14%
Sell 16.34%
Hold 8.52%
BUY
SELL
HOLD
All reports of BIOCON